← Leaderboards
Mariel Sofia Lavieri-Williams
University Of Michigan At Ann Arbor
$1,441,662
Attributed
$2,883,323
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $620.4K · FY2016–20$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,883,323 · 1
By mechanism
R01$2,883,323 · 1
Top collaborators
- Joshua D Stein5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- David C Musch$2,966,828
- Terry J Bergstrom$523,721
- Scott L Hummel$1,003,423
- Arul M Chinnaiyan$35,112,976
- Julia E Richards$9,292,844
Others in their field
Top investigators on “Intervention Studies”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,218,995
- Daniel R Kuritzkes · Brigham And Women'S Hospital$252,404,250
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$239,830,683
Research focus
Intervention StudiesAdvanced DiseaseInnovationBaseBlindnessBrainIndividual PatientAffectClinical DataClinical TrialsData ModelingDecision AidDiagnostic TestsDisease ProgressionEngineeringAmericanFoundationsFundingFutureGlaucomaGovernmentHigh RiskHypertension TreatmentMeasurement
Grant awards (5)
Personalized Forecasting of Disease Trajectory for Patients with Open Angle Glaucoma$565,175
R01 · FY2020 · EY
Personalized Forecasting of Disease Trajectory for Patients with Open Angle Glaucoma$565,175
R01 · FY2019 · EY
Personalized Forecasting of Disease Trajectory for Patients with Open Angle Glaucoma$565,175
R01 · FY2018 · EY
Personalized Forecasting of Disease Trajectory for Patients with Open Angle Glaucoma$567,439
R01 · FY2017 · EY
Personalized Forecasting of Disease Trajectory for Patients with Open Angle Glaucoma$620,359
R01 · FY2016 · EY